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Summary
Background Cervical cancer incidence remains high in several Baltic, central, and eastern European (BCEE) countries, 
mainly as a result of a historical absence of eﬀ ective screening programmes. As a catalyst for action, we aimed to 
estimate the number of women who could be spared from cervical cancer across six countries in the region during 
the next 25 years, if eﬀ ective screening interventions were introduced.
Methods In this population-based study, we applied age–period–cohort models with spline functions within a Bayesian 
framework to incidence data from six BCEE countries (Estonia, Latvia, Lithuania, Belarus, Bulgaria, and Russia) to 
develop projections of the future number of new cases of cervical cancer from 2017 to 2040 based on two future 
scenarios: continued absence of screening (scenario A) versus the introduction of eﬀ ective screening from 2017 onwards 
(scenario B). The timespan of available data varied from 16 years in Bulgaria to 40 years in Estonia. Projected rates up to 
2040 were obtained in scenario A by extrapolating cohort-speciﬁ c trends, a marker of changing risk of human 
papillomavirus (HPV) infection, assuming a continued absence of eﬀ ective screening in future years. Scenario B added 
the eﬀ ect of gradual introduction of screening in each country, under the assumption period eﬀ ects would be equivalent 
to the decreasing trend by calendar year seen in Denmark (our comparator country) since the progressive regional 
introduction of screening from the late 1960s.
Findings According to scenario A, projected incidence rates will continue to increase substantially in many BCEE 
countries. Very high age-standardised rates of cervical cancer are predicted in Lithuania, Latvia, Belarus, and Estonia 
(up to 88 cases per 100 000). According to scenario B, the beneﬁ cial eﬀ ects of eﬀ ective screening will increase 
progressively over time, leading to a 50–60% reduction of the projected incidence rates by around 2040, resulting in 
the prevention of cervical cancer in 1500 women in Estonia and more than 150 000 women in Russia. The immediate 
launch of eﬀ ective screening programmes could prevent almost 180 000 new cervical cancer diagnoses in a 25-year 
period in the six BCEE countries studied.
Interpretation Based on our ﬁ ndings, there is a clear need to begin cervical screening in these six countries as soon as 
possible to reduce the high and increasing incidence of cervical cancer over the next decades.
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Introduction
In the next few decades, several million women living in 
the Baltic, central, and eastern European (BCEE) region 
will be at high risk of developing cervical cancer. 
At present, cervical cancer incidence and mortality are 
higher in BCEE countries than elsewhere in Europe1 and 
are rising,2–4 partly due to an absence of screening 
interventions that are, at best, opportunistic with 
relatively low coverage and quality.5 Although the 
introduction of prophylactic vaccination against human 
papillomavirus (HPV) would substantially reduce the 
number of future cases of cervical cancer, the full eﬀ ect, 
in terms of a reduction in all-ages cervical cancer 
incidence, will not be detectable for more than 30 years.6 
Hence, the imple mentation of high-quality screening 
activities can still potentially play a major role in the 
prevention of cervical cancer and bridge the gap until 
the longer-term eﬀ ects of HPV vaccination programmes 
are seen.
Changes in sexual behaviour and increased exposure to 
high-risk HPV (eg, HPV-16 or HPV-18 types), the main 
cause of cervical cancer, led to increasingly higher risks 
of women developing cervical cancer in the generations 
of women born around or after the 1930–50s in most 
Lancet Oncol 2016; 17: 1445–52
Published Online
August 22, 2016
http://dx.doi.org/10.1016/
S1470-2045(16)30275-3
See Comment page 1349
International Agency for 
Research on Cancer, Lyon, 
France (S Vaccarella PhD, 
S Franceschi MD, 
M Plummer PhD, F Bray PhD); 
Russian NN Blokhin Cancer 
Research Centre, Moscow, 
Russia (D Zaridze PhD); Institute 
of Microbiology and 
Immunology, Faculty of 
Medicine, University of 
Ljubljana, Ljubljana, Slovenia 
(Prof M Poljak MD); and 
Estonian Cancer Screening 
Registry, National Institute for 
Health Development, Estonia 
(P Veerus PhD) 
Correspondence to: 
Dr Salvatore Vaccarella, 
International Agency for 
Research on Cancer, 150 cours 
Albert Thomas, 69372 Lyon 
Cedex 08, France
vaccarella@iarc.fr
Articles
1446 www.thelancet.com/oncology   Vol 17   October 2016
European countries,2–4,7 especially for those born after 
World War 2.8 Indirect evidence also suggests that 
high-risk HPV infection has become progressively 
more prevalent since the 1960s in several European 
countries,9–11 including countries in central and eastern 
Europe.12,13 In regions where high-quality, cytology-based 
cervical cancer screening programmes were imple-
mented several decades ago (eg, in northern Europe), the 
intervention has countered the increasing generational 
risks, and incidence has uniformly decreased, making 
cervical cancer a relatively rare disease. The recorded 
trends in Nordic countries have provided an important 
evidence base for the long-term eﬀ ectiveness of 
high-quality mass screening programmes since their 
introduction in the 1960s,14 a period when the incidence 
of women with cervical cancer was very high and, in 
some cases (eg, in Denmark), equivalent to that seen in 
some eastern African populations (Uganda and 
Zimbabwe) today.1 
As a catalyst for the implementation of screening 
activities, we quantiﬁ ed the maximum potential eﬀ ect of 
screening, in terms of the number of cervical cancer 
cases that could theoretically be prevented in BCEE 
countries by the year 2040, if screening were introduced 
by 2017 with a level of eﬀ ectiveness similar to that seen 
historically in Denmark. We developed a robust method 
for the projection that reﬂ ect the two underlying factors 
aﬀ ecting cervical cancer incidence: period eﬀ ects that 
reﬂ ect changes in cervical cancer risk through time, 
mimic the implementation of eﬀ ective screening 
programmes, with declining incidence downwards 
across targeted age groups; and birth cohort eﬀ ects, 
which are proxies for changes in sexual behaviour and 
increased risk of infection with high-risk HPV in 
successive generations of women.15
Methods
Study design and data sources 
In this population-based study, we ﬁ tted age–period–
cohort (APC) models to incidence data to develop 
projections of the future number of new cases of cervical 
cancer in six BCEE countries from 2017 to 2040 under 
two scenarios. In scenario A, we calculated the number of 
new cases that would have arisen in the continued absence 
of screening, and in scenario B, the number of new cases 
that would have arisen after eﬀ ective screening from 2017. 
We selected three Baltic countries (Estonia, Latvia, and 
Lithuania), and three central or eastern European 
countries (Belarus, Bulgaria, and Russia), based on the 
availability of high-quality and representative cancer 
inicidence data. For all countries except Russia, new cases 
of invasive cervical cancer were obtained from national 
population-based cancer registries of the International 
Agency for Research on Cancer’s (IARC) Cancer Incidence 
in Five Continents series, of which the most recent 
(volume X) spans to 2007. We also included available data 
beyond 2007, so the data included in this study are the 
most recently available in the countries studied at the time 
of writing. For Russia, data from 2012 were obtained from 
a national database of regional cancer registries. 
Population data were based on the country-speciﬁ c and 
age-speciﬁ c population estimates of 2015–40 from the 
United Nations Population Division (the 2010 revision).16 
Procedures and statistical analysis 
Analyses were restricted to include cervical cancer 
diagnoses at ages 30–74 years because recommended 
screening ages tend to range from 25–64 years, with 
beneﬁ cial eﬀ ects starting a few years after screening 
and extending to 74 years of age. Truncated 
age-standardised incidence rates (ASR, hereafter 
Research in context
Evidence before this study
We searched PubMed with the search terms “cervical cancer AND 
trends AND (Eastern Europe OR baltic)” and “cervical cancer AND 
(prevention OR screening) AND (Eastern Europe OR baltic)” to 
assess available evidence for time trends and historical cervical 
cancer prevention activities in each of the six countries studied in 
these regions.  There was no date or language restriciton. Despite 
some eﬀ orts, screening activities have been absent or, at best, 
opportunistic with low coverage and quality in the studied 
countries of Estonia, Lithuania, Latvia, Belarus, Bulgaria, and Russia. 
Added value of this study
As a catalyst for action, we analysed cervical cancer incidence 
from population-based cancer registries in these BCEE countries 
and projected the number of women that could be spared from 
cervical cancer diagnoses over the next 25 years in the region 
upon swift introduction in 2017 of eﬀ ective screening 
programmes. Under the assumption that screening-related 
gains could be as favourable as those shown in the long-term 
trends in cervical cancer incidence in Denmark, we estimate that 
180 000 new cases of cervical cancer could be prevented from 
2017 to 2040 in the six countries. 
Implications of all the available evidence
The scale of the rapid increase in risk in recent generations of 
women, most of whom are outside the target age range of the 
HPV vaccine, and the clear evidence of a prevention eﬀ ect can 
and must strengthen the resolve to immediately launch eﬀ ective 
screening programmes in Baltic, central, and eastern European 
countries. A lack of action will result in an increase of the number 
of women diagnosed with cervical cancer. The use of HPV 
testing-based screening programmes, as recommended by WHO 
for countries without established cytology-based programmes, 
could further accelerate the screening beneﬁ ts and, in 
combination with a prompt introduction of HPV vaccination, 
drastically reduce the burden of cervical cancer.
For the IARC’s Cancer Incidence 
in Five Continents Series see 
http://ci5.iarc.fr
For Russia’s national database 
of regional cancer registries see 
http://www.oncology.ru/service/
statistics/malignant_tumors
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referred to as incidence) adjusted for the eﬀ ect of age 
using weights of the world standard population were 
calculated by year of cancer diagnosis.17 We used the 
APC forecasting model based on our previous work 
(appendix pp 1–2).3,7 In brief, Poisson regression models 
were ﬁ tted within a Bayesian generalised additive 
models framework to summarise trends in terms of 
age, period, and cohort eﬀ ects.18 We circumvented the 
non-identiﬁ ability problem that characterises APC 
models by taking advantage of the consistent association 
between age and cervical cancer that has been recorded 
in unscreened populations (ie, a steady rise in prevalence 
up to roughly 45 years of age, followed by a plateau).19 
This pattern was also recorded in populations from 
Nordic countries in pre-screening periods. In screened 
populations, rates of cervical cancer plateau earlier—at 
about 35 years of age—because of the beneﬁ cial eﬀ ect of 
screening. We could, therefore, constrain incidence 
rates in both screened and unscreened populations to 
be equal at ages 45–49 years and 65–69 years, thus 
enabling the estimation of a unique set of parameters 
for the age, period, and cohort eﬀ ects.3,7,19,20
In scenario A, we made forecasts assuming continued 
absence of eﬀ ective screening. We obtained expected 
future incidence rates of cervical cancer up to 2040 by 
extrapolating period and cohort eﬀ ects with smoothing 
functions, under the assumption that age eﬀ ects remain 
unchanged in future years. The canonical log link 
function for APC models for period and cohort eﬀ ects was 
replaced by the corresponding ﬁ rst-order approximation 
of the Taylor series expansion for the exponential, 
resulting in more conservative projections than those that 
would be obtained by using the log link function.21 Using 
a Bayesian framework and Gibbs sampling, we obtained 
the expected number of cervical cancer cases by running 
chains of 10 000 iterations after discarding the ﬁ rst 1000 
possibly unstable samples. Samples from every tenth 
iteration were stored and the convergence of the chains 
was checked. The Rjags library was used as an interface to 
run the Just Another Gibbs Sampler software (version 
4.1.0) within R (version 3.3.0). Prediction intervals for 
future cancer incidence projections were not reported.
In scenario B, we made forecasts under the assumption 
that eﬀ ective screening in all six countries took place 
from 2017. In this second scenario, we postulated that 
the gradual eﬀ ect of implementing eﬀ ective screening 
on cervical cancer incidence would be equivalent to the 
decreasing trend by calendar year recorded in Denmark 
(our comparator country) upon early implementation of 
high-quality conventional cytology screening in the late 
1960s. The key assumption was that decreases in period-
speciﬁ c eﬀ ects in Denmark represent an achievable 
beneﬁ cial eﬀ ect of screening activities on cervical cancer 
incidence, whereas the absence of such period eﬀ ects, as 
seen in BCEE countries, represents an absence of 
eﬀ ective screening activities. Although the eﬀ ect of 
screening-related decreases was reasonably consistent 
across Nordic countries since the late 1960s, the largest 
decreases by calendar period as estimated by the APC 
analyses occurred in Denmark.3,7,20 National projections 
were based on a scenario in which high-quality screening 
would be implemented in BCEE countries in 2017, 
extrapolating the age and cohort eﬀ ects into the future, 
while projecting the equivalent period eﬀ ects only until 
2017 and, thereafter, projecting a declining trend with a 
slope equal to that estimated for period eﬀ ects in 
Denmark after the introduction of screening in the 
period from the late 1960s to 2010 (appendix pp 1–2).3,7 
We estimated the number and proportion of cervical 
cancer cases that could be prevented by screening during 
2017–40 from the diﬀ erence between projected rates 
derived in scenario A versus scenario B. Extensive 
sensitivity analyses were done (appendix).
Role of the funding source 
The funder of the study had no involvement in data 
collection, analysis, or interpretation of the results; study 
design; patient recruitment; writing of the report, or any 
See Online for appendix
Observed Projected 
Prediction base 
(timespan in years)
Mean cases 
per year, n 
Person-years*† ASR 2003–07 
per 100 000 
women 
ASR 2036–40 
with no 
screening
ASR 2036–40 
with screening 
from 2017
Cumulative 
number of 
incident cases, 
2017–40 with no 
screening
Cumulative number 
of incident cases, 
2017–40 with 
screening from 2017
Number of cervical cancer cases 
potentially preventable by 
screening (% of total with no 
screening), 2017–40 with 
screening from 2017
Estonia 1968–2007 (40) 143 0·4 35·4 64·4 31·4 4853 3392 1461 (30%)
Lithuania 1978–2007 (30) 464 1·0 45·6 87·5 43·4 16 105 11 322 4783 (30%)
Latvia 1983–2007 (25) 192 0·7 26·8 68·4 30·1 7773 5003 2770 (36%)
Belarus 1978–2007 (30) 772 2·9 26·1 67·2 30·6 34 911 22 594 12 318 (35%)
Bulgaria 1993–2008 (16) 1010 2·3 44·2 55·1 27·8 29 967 21 576 8392 (28%)
Russia 1993–2012 (20) 11 043 43·1 25·2 50·2 23·3 452 173 301 999 150 175 (33%)
Total ·· ·· ·· ·· ·· ·· ·· ·· 179 899
ASR=age-standardised incidence rate. *Average annual ﬁ gure. †Person-years expressed in millions. 
Table: Observed and projected cases and incidence of cervical cancer under diﬀ erent scenarios for women aged 30–74 years in the six countries
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aspect pertinent to the study. The corresponding author 
had full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
In total, our analysis included 280 149 recorded cases of 
cervical cancer in the six BCEE countries and approximately 
1060 million women-years of follow-up. The timespan of 
observation varied between countries, ranging from 
16 years in Bulgaria to 40 years in Estonia (table). 
The observed incidence in 2003–07 varied substantially 
across countries, ranging from roughly 25–26 cases per 
100 000 in Russia, Latvia, and Belarus to about 44–45 per 
100 000 in Lithuania and Bulgaria. The APC model eﬀ ects 
on ﬁ tting age, period, and cohort by country are presented 
in appendix p 3. No substantial changes in period-speciﬁ c 
eﬀ ects were detected within the observed data in the BCEE 
countries. Increases in cohort-speciﬁ c risks in successive 
generations of women born between the 1940s and 1950s 
were seen in all studied countries (appendix p 3). 
Under the scenario A assumption (no eﬀ ective 
screening), the projected cohort eﬀ ects will continue 
until 2040 with period eﬀ ects being quite stable 
(appendix p 3). Our projections suggest that a failure to 
introduce screening will result in more than 450 000 new 
cases of cervical cancer being diagnosed in Russia, 
35 000 in Belarus, 30 000 in Bulgaria, and more than 
25 000 combined in Estonia, Lithuania, and Latvia 
during 2017–40. The forecasts to 2040 suggest that the 
incidence will at least double in the absence of screening 
in ﬁ ve of the six countries, reaching an incidence of 
more than 60 per 100 000 for 2036–40 in Estonia, Latvia, 
and Belarus and more than 85 per 100 000 in Lithuania 
(ﬁ gure 1). A smaller increase in the forecasted incidence 
is predicted in Bulgaria where, despite the high incidence 
in 2003–07, projections of cohort-speciﬁ c eﬀ ects are 
expected to be more modest (table).
Scenario B projections suggest that the implementation 
of high-quality cervical cancer screening programmes in 
BCEE countries from 2017 will have a progressive eﬀ ect 
after the introduction of screening, with decreases in 
cervical cancer incidence projected to 2040 (ﬁ gure 1). The 
projected incidence in 2036–40 is approximately half of 
the projected rates obtained in scenario A of no eﬀ ective 
screening, which is about 30 or lower per 100 000 in all 
selected BCEE countries other than Lithuania, where the 
incidence increases to roughly 43 per 100 000 (table). 
The cumulative number of cervical cancer cases that 
could be theoretically prevented by screening during 
2017–40 varies between countries, from almost 1500 in 
Estonia to more than 150 000 in Russia (ﬁ gure 1, table). 
The percentage of new cases of cervical cancer potentially 
preventable by screening on average during the period 
2017–40 was estimated to range from 28% (Bulgaria) to 
36% (Latvia; table). This proportion, however, increases 
progressively with time, with reductions in incidence 
being similar across the six countries, reaching 50–60% 
in 2040, to the no eﬀ ective screening scenario (ﬁ gure 2). 
Discussion
Our study supports the notion that eﬀ ective screening 
programmes could have a major eﬀ ect in the next few 
decades in countries where the incidence of cervical 
cancer is frequent and implementation of screening 
activities has been limited. The beneﬁ cial eﬀ ects 
after implementation of screening in 2017 increase 
progressively over time, with a projected reduction in 
cervical cancer incidence of 50–60% by 2040 and with 
only minor diﬀ erences across the studied countries that 
are mainly due to the diﬀ erent projections for the cohort 
eﬀ ects.7,22 Our projections suggest that an increasing 
number of women in the six BCEE countries will be 
Figure 1: Observed and projected incidence of cervical cancer in six Baltic, central, and eastern European countries 
Forecasts of future cervical cancer rates according to two scenarios: no screening (red circles) and eﬀ ective 
screening commencing in 2017 (purple circles). The introduction of eﬀ ective screening shows a progressive eﬀ ect 
similar to that recorded in Denmark after the introduction of screening in the 1960s.
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diagnosed with cervical cancer during the next 30 years 
in the absence of eﬀ ective screening. Incidence in 
2036–40 is thus predicted to be similar to that observed 
in women in Denmark (incidence of approximately 
68 per 100 000) around 1960,17 before the advent of 
organised screening. According to our projections, the 
immediate launch of eﬀ ective screening programmes 
would substantially change this adverse future scenario, 
preventing almost 180 000 new diagnoses of cervical 
cancer over a 25-year period in the six countries.
Dynamic models suggest that HPV vaccination is 
expected to change all-age cervical cancer incidence only 
after several decades6 and thus will have a limited eﬀ ect on 
incidence before 2040. Bulgaria and Latvia (as well as 
Slovenia, the Czech Republic, Macedonia, Hungary, and 
Croatia) have integrated HPV vaccines into their national 
immuni sation programme started providing routine 
vaccination free of charge to adolescent girls.5 Coverage 
is not, however, reported. In Russia, only small-scale 
regional vaccination programmes have been implemented, 
resulting in more than 20 000 girls being vaccinated.23 
In most BCEE countries, including Lithuania, Estonia, 
and Belarus, HPV vac cination has yet to be incorporated 
into national programmes.5,23 However, even in the 
best-case scenario of an accelerated implementation of the 
vaccine national coverage, the next two to three generations 
of women beyond the target age for vaccination will be at 
high risk of cervical cancer.24
So far, none of the studied BCEE countries have 
established organised, high-quality or high-coverage 
cervical cancer screening programmes, and roughly the 
same situation applies to other countries in the region. 
Until recently, cytology-based screening was mainly 
opportunistic, with low coverage (at most about 20%)5 
and quality control on cytology. Some eﬀ orts, however, 
have been made,25,26 especially after the release of the 
European Union guidelines on screening in 2008.27 
The Baltic countries of Estonia, Lithuania, and Latvia 
established organised cytology-based screening pro-
grammes around 2005 that partly function, although low 
coverage, absence of quality assurance, and opportunistic 
screening outside the main programme are major 
obstacles.28,29 In Bulgaria, cervical cancer screening has 
been opportunistic for the past few decades, and plans 
for organised screening have not yet started.30 In Russia, 
and in Belarus and other countries of the former Soviet 
Union, screening is mainly opportunistic. Since 2002, 
the Moscow region reorganised screening activities 
based on a call–recall system (inviting women for 
screening on a regular basis) and the number of 
gynaecological examinations increased substantially, 
although no centralised screening database exists and 
the coverage of the targeted population is not known.23 
Romania and Croatia started organised screening in 
2012, but programme indicators have not been 
reported (Poljak M, University of Ljubjana, personal 
communication). Indeed, reliable screening indicators 
are absent in all BCEE countries, and the low participation 
rates in the screening programme point to a need for 
central governments to ensure a vastly improved popu-
lation coverage by organised screening. A particularly 
positive example comes from Slovenia, where, in a 
relatively short time and with aﬀ ordable investment, the 
country moved from an opportunistic to an organised 
national screening programme; the result was a dramatic 
drop in cervical cancer incidence rates, from 15 to 
six cases per 100 000 during 2003–15.25
None of the BCEE countries seem to have planned for 
the use of HPV-based screening which, compared with 
cytology, provides better and more durable negative 
predictive value against high-grade cervical disease, 
requires a simpler logistic and health-care infrastructure, 
is more reproducible, and is likely to be more cost 
eﬀ ective.30,31 The use of the more sensitive HPV testing is 
recommended by WHO guidelines for countries without 
an already functioning eﬀ ective, high-coverage cytology-
based programme.32 
The comparisons across diﬀ erent areas in Europe 
sharing similar underlying risk factors allowed us to 
build projections for BCEE countries in a scenario where 
the possible future onset of screening activities could 
theoretically produce a similar eﬀ ect on cervical cancer 
risk as that produced historically in Nordic countries. 
Adopting the principles of pre ventability, Denmark was 
Figure 2: Estimated percentage of cervical cancer cases expected to be potentially preventable by screening 
in 2040 in six Baltic and eastern European countries
The percentage of cervical cancer cases prevented is calculated as: projected 1–projected 2 × 100/projected 1. 
Projected cases are derived from a modiﬁ ed age–period–cohort model. Projected 1=projected cases in a scenario 
that assumes no improvements in present cervical cancer screening activities (scenario A). Projected 2=projected 
cases in a scenario that assumes that eﬀ ective screening will start in 2017 (scenario B). 
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chosen as the reference country because, of the Nordic 
countries, it had the largest screening-related decrease in 
period eﬀ ects and therefore represented the largest 
prevention gain through cytology-based screening.3 
Furthermore, rates of cervical cancer in Denmark in the 
1960s were even higher compared with BCEE countries, 
possibly because of diﬀ erences in sexual behaviour and 
persistent high-risk HPV infections. Prevalences of 
cervical cancer in the BCEE countries studied are now 
approaching those recorded in Denmark in the 
pre-screening years. Despite varying baseline incidence, 
the relative eﬀ ect of screening in driving down incidence 
has been quite consistent across Nordic countries.7 
We therefore believe that the use of diﬀ erent reference 
countries would not have changed our projected scenarios 
substantially. Although the estimated risk reduction 
might be over-optimistic if BCEE countries are unable to 
implement screening programmes that are as eﬀ ective as 
those implemented in Nordic countries in the past, our 
projection allows an estimate of the upper limit of cervical 
cancer cases that are preventable by cytology-based 
programmes. The use of the HPV test as the primary test 
would most probably enhance screening eﬀ ectiveness, 
and lead to an even greater number of prevented cervical 
cancer cases, provided that high coverage quality control 
of test results, exhaustive work-up, and, when necessary, 
treatment of screening-positive women were in place. 
Additionally, the higher sensitivity of HPV testing enables 
screening to begin after age 30 years and the adoption of 
longer screening intervals.
Our approach circumvented the non-identiﬁ ability 
problem of the APC models based on the observation of a 
uniform age curve for cervical cancer incidence, thus 
allowing the estimation of a unique set of parameters 
for period and cohort eﬀ ects. Although there are no 
identiﬁ ability issues in projecting future incidence 
rates,33,34 speciﬁ c parameterisations of period and cohort 
trends were essential in our analysis to ensure appropriate 
interpretation of cervical cancer incidence trends and the 
development of alternative scenarios of future burden. 
Screening is expected to deﬂ ect the incidence trends 
downward across all targeted age groups and this should 
be visible as a period eﬀ ect, whereas changes in risk 
factors chieﬂ y manifest themselves as variations in risk 
across successive birth cohorts of women (ie, a cohort 
eﬀ ect). Strong support for such an interpretation of the 
risk proﬁ le of period and cohort eﬀ ects is gained by the 
results from previous analyses that compared the eﬀ ect of 
long-term screening programmes (in Nordic countries) 
with their absence (in eastern European and Baltic 
countries).2,3 Nordic countries and eastern European 
countries showed similar increases in cervical cancer 
prevalence in the birth cohorts born after 1950,3 probably 
due to a progressive increase in the risk of HPV exposure. 
However, these regions diﬀ er when assessing period 
eﬀ ects. In Nordic countries, the strong period-related 
decreases are visible and the consequences of rising 
high-risk HPV-related generational risks are largely 
negated.3,7,20 Conversely, in BCEE countries, where 
screening-related eﬀ ects are absent, the result is a 
remarkable and avoidable rise in future cervical cancer 
incidence, reﬂ ecting the increasing risk in successive 
generations of women. 
A possible limitation of this study is that the projected 
generational risks were based on trends recorded in the 
youngest generations of women, for which data might be 
sparse, and were assumed to continue to increase across 
the whole study period. However, we cannot exclude that 
the direction and magnitude of future generational risks 
might diﬀ er from the assumptions we made in this 
analysis. Distinct observable changes in cohort eﬀ ects 
have been noted in historical trends (eg, a U-shaped 
pattern in several European countries), with decreases in 
cervical cancer cases before the introduction of screening 
reported for generations of women born during 1920–30 
followed by risk increases in successive generations. 
Previous reports have postulated that cohort eﬀ ects for 
the risk of some cancers, including cervical cancer, might 
follow a roughly cyclical pattern.35,36 However, the patterns 
found in our study seem irregular and vary by country, 
mainly related to diﬀ erent changes in sexual behaviour 
and perhaps parity, which is also a risk factor for cervical 
cancer. The use of spline functions to parametrise our 
model enabled a ﬂ exible assessment of changing 
patterns, including possible cyclical patterns, of the 
cohort eﬀ ects within the prediction base and a projection 
of the most recent trend into the future. Mathematical 
transmission models would help to understand the 
future generational trends, although they would require 
a number of additional assumptions about the sexual 
habits and spread of HPV infection in diﬀ erent 
populations. Ideally, dynamic models should be 
integrated with statistical models that enable projections 
based on recorded incidence data, such as in the present 
study. Extensive sensitivity analyses using diﬀ erent 
assumptions were done (appendix). Other sensitivity 
analyses were also done, including assumptions of a 
lower eﬀ ect of the screening-related period eﬀ ects than 
that estimated for Denmark. With respect to the quality 
of incidence data, the completeness of cervical cancer 
reports is an obvious concern. Notably, the national 
cancer data from Russia, which comes from 
population-based registration on a regional basis, might 
be incomplete. The inclusion of this country in our 
present study is nevertheless useful because it included 
the largest population in the BCEE region. 
We cannot precisely estimate the future incidence rates 
and burden of cervical cancer and it is possible that 
trends will evolve diﬀ erently from those predicted by our 
model. Consistent with other studies,9,37–39 we did not 
report uncertainty intervals for cancer incidence 
projections. Predictions by their nature are fraught with 
future uncertainty and, until methodological develop-
ments allow meaningful uncertainty intervals to be 
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estimated, several authors have explicitly discouraged 
their reporting.38,40–42 Our projections represent the best 
possible assessment of future scenarios given the data 
available and it is reassuring that forecasts obtained with 
a diﬀ erent method (NORDPRED), produced very similar 
results for the scenario with no future screening 
improvements. We restricted our analyses to age groups 
that are usually targeted for cervical cancer screening and 
extended them to age groups where the protective eﬀ ect 
of screening is strong. 
At present, cervical cancer screening as well as HPV 
vaccination are restricted or ineﬀ ective in BCEE 
countries. HPV vaccination is the best strategy for 
preventing cervical cancer in BCEE countries in the long 
term, yet strengthening screening activities is a key 
intervention to prevent a future increase in cervical 
cancer diagnoses in the next two or three generations of 
women.5 Protocols combining HPV vaccination of 
adolescents with several rounds of organised HPV-based 
screening have been proposed as a viable option in 
high-risk populations such as the BCEE countries.31,32 
In the absence of action, the cervical cancer risk in 
women living in these countries might reach levels 
similar to those seen in some sub-Saharan African 
countries today43 and in Denmark half a century ago.44
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